Relapsing-remitting Multiple Sclerosis research hub
4 indexed studies · 2 currently recruiting
- active not recruitingPHASE3
A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-remitting Multiple Sclerosis (RRMS)
This study looks at a new medicine called ocrelizumab for children and teenagers aged 10-17 with a type of MS called relapsing-remitting multiple sclerosis (RRMS). It compares ocrelizumab to an existing medicine, fingolimod, to see how safe and effective it is over a period of time.
United States · Argentina · Australia - recruiting
Study to Evaluate the Usability and Value of Integrated Digital Solutions in Medical Care of Participants With Multiple Sclerosis
This study looks at a new digital system for people with Relapsing Remitting Multiple Sclerosis (RRMS). It checks how helpful and easy to use two tools are: one that analyses brain scans with AI, and a phone app and website for tracking health and helping with doctor visits.
United States · Germany - recruitingPHASE1
SIZOMUS Safety of Ixazomib Targeting Plasma Cells in Multiple Sclerosis
This study is investigating a new drug called ixazomib to see if it's safe and helpful for people with different types of multiple sclerosis (MS). We want to find out if it can reduce certain markers in the fluid around the brain and spinal cord.
United Kingdom - ongoing, recruitingTherapeutic confirmatory (Phase III)
Open-Label, Randomized, Multicenter, Multi-Dose, Active Controlled, Parallel-Group, Efficacy and Safety Study of BG00012 in Children from 10 to Less Than 18 Years of Age with Relapsing-Remitting Multiple Sclerosis with Optional Open-Label Extension (CONNECT)
This study looks at a medicine called BG00012 for children and teenagers aged 10 to under 18 with a type of multiple sclerosis (MS). It aims to see how well it works in preventing new MS brain lesions and to check its safety, comparing it with an existing treatment.
France